MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/bjsopen/zrae054

Медицинская библиотека · BJS open · 2024

Surgical and multimodal treatment of metastatic oesophageal cancer: retrospective cohort study.

Knipper Karl, Lemties Julian, Krey Thaddaeus, Lyu Su Ir, Wirsik Naita M, Schiffmann Lars M, Fuchs Hans F, Gebauer Florian, Schröder Wolfgang, Popp Felix C, Quaas Alexander, Schlößer Hans A, Bruns Christiane J, Schmidt Thomas

СтатьяПеревод в очереди

Аннотация

BACKGROUND

In contrast to the well-established multimodal therapy for localized oesophageal cancer, the metastatic stage is commonly treated only with systemic therapy as current international guidelines recommend. However, evidence suggesting that multimodal therapy including surgery could benefit selected patients with metastasized oesophageal cancer is increasing. The aim of this study was to investigate the survival of patients diagnosed with metastatic oesophageal cancer after different treatment regimens.

METHODS

This was a retrospective single-centre study of patients with adenocarcinoma or squamous cell carcinoma of the oesophagus with synchronous or metachronous metastases who underwent Ivor Lewis oesophagectomy between 2010 and 2021. Each patient received an individual treatment for their metastatic burden based on an interdisciplinary tumour board conference. Survival differences between different treatments were assessed using the Kaplan-Meier method, as well as univariable and multivariable Cox regression models.

RESULTS

Out of 1791 patients undergoing Ivor Lewis oesophagectomy, 235 patients diagnosed with metastases were included. Of all of the included patients, 42 (17.9%) only underwent surgical resection of their metastatic disease, 37 (15.7%) underwent multimodal therapy including surgery, 78 (33.2%) received chemotherapy alone, 49 (20.9%) received other therapies, and 29 (12.3%) received best supportive care. Patients who underwent resection or multimodal therapy including surgery of their metastatic burden showed superior overall survival compared with chemotherapy alone (median overall survival of 19.0, 18.0, and 11.0 months respectively) (P < 0.001). This was confirmed in subcohorts of patients with metachronous solid-organ metastases and with a single metastasis. In multivariable analyses, resection with or without multimodal therapy was an independent factor for favourable survival.

CONCLUSION

Surgical resection could be a feasible treatment option for metastasized oesophageal cancer, improving survival in selected patients. Further prospective randomized studies are needed to confirm these findings and define reliable selection criteria.

Для цитирования: Knipper Karl, Lemties Julian, Krey Thaddaeus, Lyu Su Ir, Wirsik Naita M, Schiffmann Lars M, Fuchs Hans F, Gebauer Florian, Schröder Wolfgang, Popp Felix C, Quaas Alexander, Schlößer Hans A, Bruns Christiane J, Schmidt Thomas. Surgical and multimodal treatment of metastatic oesophageal cancer: retrospective cohort study.. BJS open. 2024. DOI: 10.1093/bjsopen/zrae054.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.